Community Resource Initiative

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 - Merck.com DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral treatment DOR/ISL maintained virologic suppression at Week 96 in adults with virologically...

Doravirine/Islatravir Combination Maintains Virologic Suppression Through 96 Weeks | Contagion Live Amy Colson, MD, MPH, discusses data from the MK8591A-052 trial which showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide.

NEW: A phase 2 study from Gilead Sciences and Merck finds that once-weekly oral islatravir plus lenacapavir (ISL+LEN) maintained high rates of virologic suppression at 48 weeks in people with HIV-1 with no serious adverse events. These results suggest that ISL+LEN may offer a promising once-weekly treatment regimen that could help address adherence challenges in HIV care. https://bit.ly/4p6X5Ek

Amy Colson, MD, MPH, recently discussed phase 2 data showing durable virologic suppression, low resistance risk, and favorable safety with weekly oral islatravir plus lenacapavir in suppressed adults with HIV.

Read the interview here:

Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks | Contagion Live Amy Colson, MD, MPH, discusses phase 2 data showing durable virologic suppression, low resistance risk, and favorable safety with weekly oral islatravir plus lenacapavir in suppressed adults with HIV.

"These results provide reassurance that the transition from daily to once-weekly dosing does not have an adverse effect on adherence and offers a favorable outlook for long-acting treatment strategies," Colson and colleagues wrote. "Offering a range of treatment options with differing administration routes and dosing intervals remains important to meet the diverse needs of persons with HIV-1 and minimize barriers to antiretroviral therapy adherence."

Read more here:

Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression And islatravir plus lenacapavir could help boost treatment adherence, phase II trial suggests

As we reflect on this past year at CRI, we are deeply grateful for the unwavering support of donors like you. Your generosity has given hope to Massachusetts residents facing the challenges of HIV and other infectious diseases. Together, we have continued our mission to provide life-saving access to treatment, including prevention medications, and striving for health equity for our most vulnerable neighbors. But our work does not stop here. Please consider making a donation today, Giving Tuesday.

https://crine.app.neoncrm.com/forms/end-of-year-2025?campaignId=286

Access to prevention remains a cornerstone of our work. This year, with your help, CRI expanded our outreach and education efforts, ensuring that more people have information about and access to effective prevention. These initiatives are vital in reducing new infections and promoting overall community health.

As we face new challenges and shifting federal funding, your unrestricted support is crucial. On Giving Tuesday, we invite you to make a year-end gift to CRI. Your generosity will ensure that everyone, regardless of circumstance, receives the care and dignity they deserve. Together, we can build a future free from HIV, full of hope and opportunity.

https://crine.app.neoncrm.com/forms/end-of-year-2025?campaignId=286

As we mark World AIDS Day on December 1st, we pause to honor the resilience and courage of everyone affected by HIV in Massachusetts and beyond. At CRI, this day renews our commitment to ending stigma, supporting those in need, and advancing health equity for all. Thanks to your continued generosity, our community is stronger and more hopeful than ever before.

Today, CRI team members—Gerry, Wilfredo, and Steve—are representing our organization at the World AIDS Day event at Cyclorama. Yesterday, Steve joined the Ryan White Planning Council and helped carry the commemorative quilt from City Hall Plaza, honoring those we’ve lost and the ongoing fight against HIV.

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials

Mark Giese is set to take on the journey from Boston to Provincetown this Saturday as part of the Annual OutRider's Bike Ride, a cherished tradition that brings cyclists together for a scenic and celebratory ride. While the event is primarily a social ride, Mark has chosen to make his participation even more meaningful by turning it into a fundraising effort for CRI.

His dedication to our mission highlights the importance of community engagement and advocacy, ensuring that vital resources and programs remain accessible to those in need. Through his ride, Mark not only raises funds but also awareness, reinforcing CRI’s commitment to fostering support, inclusivity, and lasting impact within the community.

To support Mark's efforts, you can make a donation to his campaign here: https://crine.app.neoncrm.com/campaigns/markgiese2025

Year-round, CRI actively participates in a diverse range of outreach and community events, ensuring meaningful connections with individuals and organizations. By engaging in gatherings such as PRIDE events and other community-focused initiatives, CRI provides vital information about our programs and resources while fostering open dialogue.

Read more about how CRI is in the community is the Summer Issue of CRI Access e-newsletter here: https://shorturl.at/LMzcN